Revvity, Inc. Files 8-K on Financials
Ticker: RVTY · Form: 8-K · Filed: Jan 13, 2025 · CIK: 31791
Sentiment: neutral
Topics: financial-results, regulation-fd, corporate-actions
Related Tickers: PKI
TL;DR
Revvity (PKI) dropped an 8-K on Jan 13th detailing financial results and Reg FD. Formerly PerkinElmer.
AI Summary
Revvity, Inc. filed an 8-K on January 13, 2025, reporting results of operations and financial condition as of January 12, 2025. The filing also includes a Regulation FD Disclosure. Revvity, Inc. was formerly known as PerkinElmer Inc. and is headquartered in Waltham, Massachusetts.
Why It Matters
This 8-K filing provides crucial updates on Revvity, Inc.'s financial performance and operational status, which is important for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting financial information and is not indicative of immediate significant risk.
Key Players & Entities
- Revvity, Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Date of Report
- PerkinElmer Inc. (company) — Former Company Name
- Waltham, Massachusetts (location) — Company Headquarters
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Revvity, Inc.'s Results of Operations and Financial Condition, as well as to provide a Regulation FD Disclosure.
On what date was this 8-K report filed?
This 8-K report was filed on January 13, 2025.
What was Revvity, Inc. formerly known as?
Revvity, Inc. was formerly known as PerkinElmer Inc.
Where is Revvity, Inc. headquartered?
Revvity, Inc. is headquartered at 77 4th Avenue, Waltham, Massachusetts 02451.
What is the SIC code for Revvity, Inc.?
The Standard Industrial Classification (SIC) code for Revvity, Inc. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-13 07:20:38
Key Financial Figures
- $1 — nge on which registered Common stock, $1 par value per share RVTY The New York S
Filing Documents
- pki-20250112.htm (8-K) — 40KB
- q42024pre-earningspressrel.htm (EX-99.1) — 23KB
- jpm2025_final.htm (EX-99.2) — 17KB
- jpm2025_final001.jpg (GRAPHIC) — 82KB
- jpm2025_final002.jpg (GRAPHIC) — 202KB
- jpm2025_final003.jpg (GRAPHIC) — 106KB
- jpm2025_final004.jpg (GRAPHIC) — 76KB
- jpm2025_final005.jpg (GRAPHIC) — 121KB
- jpm2025_final006.jpg (GRAPHIC) — 93KB
- jpm2025_final007.jpg (GRAPHIC) — 113KB
- jpm2025_final008.jpg (GRAPHIC) — 93KB
- jpm2025_final009.jpg (GRAPHIC) — 137KB
- jpm2025_final010.jpg (GRAPHIC) — 91KB
- jpm2025_final011.jpg (GRAPHIC) — 133KB
- jpm2025_final012.jpg (GRAPHIC) — 127KB
- jpm2025_final013.jpg (GRAPHIC) — 77KB
- jpm2025_final014.jpg (GRAPHIC) — 79KB
- jpm2025_final015.jpg (GRAPHIC) — 119KB
- jpm2025_final016.jpg (GRAPHIC) — 120KB
- jpm2025_final017.jpg (GRAPHIC) — 104KB
- jpm2025_final018.jpg (GRAPHIC) — 83KB
- jpm2025_final019.jpg (GRAPHIC) — 92KB
- jpm2025_final020.jpg (GRAPHIC) — 139KB
- jpm2025_final021.jpg (GRAPHIC) — 122KB
- 0000031791-25-000003.txt ( ) — 3443KB
- pki-20250112.xsd (EX-101.SCH) — 3KB
- pki-20250112_def.xml (EX-101.DEF) — 16KB
- pki-20250112_lab.xml (EX-101.LAB) — 28KB
- pki-20250112_pre.xml (EX-101.PRE) — 17KB
- pki-20250112_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 12, 2025, Revvity, Inc. (the "Company") announced preliminary expectations with respect to certain financial results for the fourth quarter ended December 29, 2024 and announced that the Company will release its fourth quarter and full year 2024 financial results on January 31, 2025 . The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On January 13, 2025, Dr. Prahlad Singh, President and Chief Executive Officer of the Company, is scheduled to make a presentation to the 43rd Annual J. P. Morgan Healthcare Conference. A copy of the presentation materials is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1* Press Release entitled "Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance", issued by Revvity, Inc. on January 12, 2025. 99.2* Revvity, Inc. Presentation to the 43rd Annual J.P. Morgan Healthcare Conference, January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL) * This exhibit relating to Item 2.02 and 7.01 shall be deemed to be furnished, and not filed.. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVVITY, INC. Date: January 13, 2025 By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer